Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H24O7 |
| Molecular Weight | 376.4004 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CC2=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=CC=C2)C=C1
InChI
InChIKey=HFLCZNNDZKKXCS-OUUBHVDSSA-N
InChI=1S/C20H24O7/c1-25-14-8-6-12(7-9-14)10-13-4-2-3-5-15(13)26-20-19(24)18(23)17(22)16(11-21)27-20/h2-9,16-24H,10-11H2,1H3/t16-,17-,18+,19-,20-/m1/s1
| Molecular Formula | C20H24O7 |
| Molecular Weight | 376.4004 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sergliflozin, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves hyperglycemia by suppressing renal glucose reabsorption, in which SGLT2 participates as a dominant transporter. Its prodrug form, sergliflozin etabonate, is orally available and is converted to sergiflozin upon absorption. Development of sergliflozin has been discontinued in favor of remogliflozin.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. | 2011-04-28 |
|
| Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. | 2011-01-13 |
|
| Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. | 2010-06 |
|
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. | 2007-01 |
Sample Use Guides
A phase I study with 50–500 mg of sergliflozin in 14 healthy volunteers and a phase IIa study where the same dose range was given to eight subjects with T2DM showed a dose-dependent increase in urinary glucose excretion that plateaued at higher doses. It did not cause hypoglycemia in nondiabetic subjects, and there was a 1.5-kg weight loss from baseline to d 15 compared with placebo.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:21:47 GMT 2025
by
admin
on
Mon Mar 31 22:21:47 GMT 2025
|
| Record UNII |
AR34521QFL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00189662
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY | |||
|
360775-96-8
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY | |||
|
300000042190
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY | |||
|
AR34521QFL
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY | |||
|
Sergliflozin
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY | |||
|
10177526
Created by
admin on Mon Mar 31 22:21:47 GMT 2025 , Edited by admin on Mon Mar 31 22:21:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
